User menu

Beware of the commercialization of human cells and tissues: situation in the European Union.

Bibliographic reference Pirnay, Jean-Paul ; Vanderkelen, Alain ; Ectors, Nadine ; Delloye, Christian ; Dufrane, Denis ; et. al. Beware of the commercialization of human cells and tissues: situation in the European Union.. In: Cell and Tissue Banking, Vol. 13, no. 3, p. 487-498 (2012)
Permanent URL
  1. AFSSAPS Alert Department (2008) Alert regarding an AFSSAPS request for recall of bone products supplied by ‘Ost-Developpement’. . Accessed 3 Apr 2012
  2. Akst J (2010) Key cancer patents killed. The scientist. . Accessed on 3 Apr 2012
  3. Birger J (2006) Give me some skin. Fortune Magazine. . Accessed 3 Apr 2012
  4. Blakeslee S (2002) Lack of oversight in tissue donation raising concerns. The New York Times. . Accessed 3 Apr 2012
  5. Blasszauer B, Petty corruption in health care., 10.1136/jme.23.3.133
  6. Brand A., Rebulla P., Engelfriet C. P., Reesink H. W., Beguin Y., Baudoux E., Kögler G., Ebrahimi M., Grazzini G., Costa A. Nanni, Bosi A., Sacchi N., Lombardini L., Pupella S., Lecchi L., Calderón Garcidueñas E. D., van Beckhoven J. M., de Wit H. J. C., Fibbe W. E., Zhiburt E. B., Bart T., Beksaç M., Navarrete C., Regan F., Cord blood banking, 10.1111/j.1423-0410.2008.01106.x
  7. Bruno J James, Senderoff Douglas M., Fracchia John A., Armenakas Noel A., Reconstruction of Penile Wounds following Complications of AlloDerm-Based Augmentation Phalloplasty : , 10.1097/01.prs.0000245340.95313.d9
  8. Chrisafis A (2011) French government ‘to order women to remove defective breast implants’. The Guardian. . Accessed 3 Apr 2012
  9. Collins S (2001) Tissue Banks: Is the Federal Government’s Oversight Adequate? Hearing before the Committee on Governmental Affairs. US Senate Diane Pub Co, Washington
  10. Council of Europe (2009) Trafficking in organs, tissues and cells and trafficking in human beings for the purpose of the removal of organs. Joint Council of Europe/United Nation study. . Accessed 4 Apr 2012
  11. De Corte Peter, Verween Gunther, Verbeken Gilbert, Rose Thomas, Jennes Serge, De Coninck Arlette, Roseeuw Diane, Vanderkelen Alain, Kets Eric, Haddow David, Pirnay Jean-Paul, Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: improved performance, usability, quality and safety, 10.1007/s10561-011-9247-3
  12. de Kort W., Verhagen C., Why money should not be the first (t)issue, 10.1111/j.1751-2824.2008.00173.x
  13. Farrugia Albert, When do tissues and cells become products? – Regulatory oversight of emerging biological therapies, 10.1007/s10561-006-9012-1
  14. Faulkner Alex, Kent Julie, Geesink Ingrid, FitzPatrick David, Purity and the dangers of regenerative medicine: Regulatory innovation of human tissue-engineered technology, 10.1016/j.socscimed.2006.06.006
  15. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (2009) Ministerieel Besluit tot vaststelling van de prijs van menselijk lichaamsmateriaal. Staatsblad, 23 oktober 2009. . Accessed 3 Apr 2012
  16. Fehily D (2011) Vigilance and surveillance of substances of human origin—The SOHO V&S project. In: 6th World Congress in Tissue Banking, Barcelona
  17. Friedman M (1970) The social responsibility of business is to increase its profits. New York Times Magazine. . Accessed 4 Apr 2012
  18. Henkel J (1994) Safeguarding human tissue transplants. FDA Consum Mag 28:9–13
  19. Hermans Michel H.E., Preservation methods of allografts and their (lack of) influence on clinical results in partial thickness burns, 10.1016/j.burns.2011.01.007
  20. Hoeyer Klaus, An anthropological analysis of European Union (EU) health governance as biopolitics: The case of the EU tissues and cells directive, 10.1016/j.socscimed.2010.02.040
  21. Hunter D, Oultram S, The challenge of "sperm ships": the need for the global regulation of medical technology, 10.1136/jme.2007.021303
  22. Hurt H (2010) King of beers, and a slippery throne. The New York Times. . Accessed 3 Apr 2012
  23. Imahara SD, Klein MB (2009) Skin grafts. In: Orgill D, Blanco C (eds) Biomaterials for treating skin loss. Woodhead Publishing and CRC Press LLC, Cambridge
  24. Kearney J (2011) Tissue engineering. In: 6th World Congress in Tissue Banking, Barcelona
  25. Keller M, Grill M (2009) Inside a creepy global body parts business. Spiegel Online.,1518,druck-645375,00.html . Accessed 4 Apr 2012
  26. Kirkland Mark, The precautionary principle: a double edged sword?, 10.1007/s10561-010-9182-8
  27. Kishore R R, Human organs, scarcities, and sale: morality revisited, 10.1136/jme.2004.009621
  28. Lenk Christian, Beier Katharina, Is the commercialisation of human tissue and body material forbidden in the countries of the European Union?, 10.1136/jme.2010.038760
  29. Levitt T (1983) The globalization of markets. Harv Bus Rev 61:92–102
  30. Marcus C (1985) Spectre of commercialism dominates transplant symposium. Can Med Assoc J 133:314–317
  31. McMichael Philip, The impact of globalisation, free trade and technology on food and nutrition in the new millennium, 10.1079/pns200088
  32. Pushpa M Bhargava, On the critical assessment of the impact of the recent European Union Tissues and Cells Directive, 10.1016/s1472-6483(10)60953-4
  33. Norman BP (2000) Controversy: do corporations have any responsibility beyond making a profit? J Mark Moral 3:1–3
  34. Perlman E (2011) The cheese police. The world on cheese culture. . Accessed 3 Apr 2012
  35. Pirnay Jean-Paul, Vanderkelen Alain, Zizi Martin, De Vos Daniel, Rose Thomas, Laire Geert, Ectors Nadine, Verbeken Gilbert, Human cells and tissues: the need for a global ethical framework, 10.2471/blt.09.074542
  36. Rahmanian-Schwarz Afshin, Beiderwieden Anna, Willkomm Lina-Marie, Amr Amro, Schaller Hans-Eberhard, Lotter Oliver, A clinical evaluation of Biobrane® and Suprathel® in acute burns and reconstructive surgery, 10.1016/j.burns.2011.07.010
  37. Redfern M, Keeling JW, Powell E (2001) The Royal Liverpool children’s inquiry report. HMSO, London
  38. Schumer C (2007) A bill to improve the oversight and regulation of tissue banks and the tissue donation process, and for other purposes. Bill introduced in the Senate of the United States. . Accessed 3 Apr 2012
  39. Simoens Steven, Health economics of market access for biopharmaceuticals and biosimilars, 10.3111/13696990903260094
  40. Smith Katherine E., Fooks Gary, Collin Jeff, Weishaar Heide, Mandal Sema, Gilmore Anna B., “Working the System”—British American Tobacco's Influence on the European Union Treaty and Its Implications for Policy: An Analysis of Internal Tobacco Industry Documents, 10.1371/journal.pmed.1000202
  41. Spurgeon B., French doctors are tried for treating children with infected growth hormone, 10.1136/bmj.39489.717292.c2
  42. , Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul, 10.1016/s0140-6736(08)60967-8
  43. Terino EO (1998) Alloderm acellular dermal graft: applications in esthetic and reconstructive soft tissue augmentation. In: Klein AW (ed) Tissue augmentation in clinical practice: procedures and techniques. Marcel Dekker Inc, New York, pp 349–379
  44. TiGenix (2011) Business and financial update for the first quarter of 2011. . Accessed 3 Apr 2012
  45. van Veen E-B, Lamers C (2006) Research integrity: selling the stem cell dream stopped in the Netherlands. Telegraft 13:7–8
  46. Waltz Emily, News Feature: The body snatchers, 10.1038/nm0506-487
  47. World Health Organization Europe (2008). Guidance on developing quality and safety strategies with a health system approach. . Accessed 3 Apr 2012
  48. Yessian (2001) Informed consent in tissue donation – expectations and realities. Office of Inspector General, Department of Health and Human Services, Washington, DC. . Accessed 3 Apr 2012